EUVIMEDEUVIMED entdecken
Crossref

Venetoclax pharmacokinetics in participants with end‐stage renal disease undergoing haemodialysis

Behnam Noorani iD, Rajeev M Menon iD, Xin Chen, Kennan C Marsh, Weize Huang, Shelly Gupta, Edyta Dobkowska, Thomas Marbury iD, Ahmed Hamed Salem iD

British Journal of Clinical Pharmacology · 2024

DOI: 10.1111/bcp.15935 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Behnam Noorani und 8 weiteren Autor:innen. Beteiligte Einrichtung: AbbVie, Inc., North Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Kidney Failure, Chronic, Renal Insufficiency, Bridged Bicyclo Compounds, Heterocyclic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: AbbVie, Genentech.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Renal insufficiency is a common comorbidity in patients with haematological malignancies. This study aimed to assess how end‐stage renal disease (ESRD) might affect the pharmacokinetics of venetoclax, a Bcl‐2 inhibitor, in participants with ESRD undergoing haemodialysis.

Methods

Venetoclax was administered as a single 100‐mg dose to 6 female participants with ESRD (estimated glomerular filtration rate 90 mL/min). Intensive pharmacokinetic and protein binding samples were collected from all participants. Arterial and venous samples were collected from ESRD participants during haemodialysis to assess the effect of haemodialysis on venetoclax pharmacokinetics. Pharmacokinetic parameters were estimated using noncompartmental methods.

Results

There was no difference in plasma venetoclax concentrations between arterial and venous samples, suggesting that haemodialysis did not affect the pharmacokinetics of venetoclax. The fraction unbound ( f u ) of venetoclax was ~2‐fold higher for participants with ESRD compared to participants with normal renal function. The unbound maximum plasma concentration and area under the plasma concentration–time curve from time 0 to 48 h were comparable between ESRD and normal function groups. The mean half‐life ranged from 10.4 to 12.2 h across groups, demonstrating that ESRD did not affect the half‐life of venetoclax. No new safety signals were observed during this study.

Conclusion

ESRD and dialysis do not alter unbound venetoclax plasma concentrations. No pharmacokinetics driven dose adjustment is needed for patients with renal insufficiency.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney Failure, ChronicRenal InsufficiencyBridged Bicyclo Compounds, HeterocyclicHumansFemaleRenal DialysisSulfonamidesArea Under Curve

Stichwörter der Autor:innen

end-stage renal diseasehaemodialysispharmacokineticsrenal impairmentvenetoclax

Substanzen

venetoclaxSulfonamidesBridged Bicyclo Compounds, Heterocyclic

Autor:innen und Institutionen

  • AbbVie, Inc., North Chicago, Illinois, USA.
  • Genentech Inc., South San Francisco, California, USA.
  • Pharmacyclics, an AbbVie company in Switzerland, Schaffhausen, Switzerland.
  • Orlando Clinical Research Center, Orlando, Florida, USA.
  • Clinical Pharmacy, Ain Shams University, Cairo, Egypt.

ORCID-Profile: Behnam Noorani, Rajeev M Menon, Thomas Marbury, Ahmed Hamed Salem

Förderung

  • AbbVie
  • Genentech

Zitieren

APA

Noorani, B., Menon, R. M., Chen, X., Marsh, K. C., Huang, W., Gupta, S., Dobkowska, E., Marbury, T., & Salem, A. H. (2024). Venetoclax pharmacokinetics in participants with end‐stage renal disease undergoing haemodialysis. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15935

Vancouver

Noorani B, Menon RM, Chen X, Marsh KC, Huang W, Gupta S, et al. Venetoclax pharmacokinetics in participants with end‐stage renal disease undergoing haemodialysis. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.15935

BibTeX
@article{Noorani2024,
  author = {Noorani, Behnam and Menon, Rajeev M and Chen, Xin and Marsh, Kennan C and Huang, Weize and Gupta, Shelly and Dobkowska, Edyta and Marbury, Thomas and Salem, Ahmed Hamed},
  title = {Venetoclax pharmacokinetics in participants with end‐stage renal disease undergoing haemodialysis},
  journal = {British Journal of Clinical Pharmacology},
  year = {2024},
  doi = {10.1111/bcp.15935}
}
Kostenlos starten →